There is a need to utilize the vast data generated in -omics research to develop biomarker panels for better prediction of cardiovascular disease (CVD) risks.
•Cardiovascular diseases develop over decades and different panels of markers may be required for different stages
•Lead molecules as potential biomarkers need to be selected by a panel of experts
•Standard procedures about sample preparation, data acquisition, and analysis need to be developed
•The measurement of the markers need to be scalable and can be done in high throughput
•Specificity of the biomarkers need to be validated in animal models first and then in human